Cognizance about male infertility market offerings to provide higher returns

One out of every eight couples with intentions to procreate across the globe, suffer from infertility complications. Moreover, global statistics reveal that among the total cases of infertility, 20% of them are influenced by male biological factors. Male infertility, as the case may be referred to, is deduced from the inability to impregnate coital female partner despite regular unprotected intercourse for over a year. During recent past, there has been a rise in registered number of male infertility cases. It has been observed that the male infertility market has grown considerably during the same period. The latest report on the immature industry’s progress by Allied Market Research (AMR) forecasts the market size by 2020 to reach a net worth of $301.5 million. Compound annual growth rate, or the CAGR is expected to be 5%. throughout 2014 to 2020 The urban population becoming more expressive about sensitive issues, in the light of equal treatment of both genders, the market witnesses an expanding consumer base over the present decade.

Dealing with rarity of healthy belief system
Factors that restrain affected population from seeking professional help lies within human psychology of guilt, insult, or stress. Human hesitation comes in the way of initial acceptance of existing crisis among couples. Additionally, societal norms and misguided beliefs have set up a common notion where the female partner is held liable for not being able to conceive. This hinders with concentrating efforts on diagnosis of male infertility in the first place. Regions where patriarchal societies prevail, tend to have lesser affinity to adopt medical practices that provides cure, or alternative solutions, to such biological conditions. Spreading complete awareness regarding possible medical interventions is one solution that the corporate players have summed up from their studies. 

Parallel to that several other myths run deep in the consumer base for male infertility market. Complexity introduced by electromagnetic waves in constant vicinity and those associated with assistive reproductive technology remain primary among these. Collaborative efforts from companies and healthcare facilities intend to gradually bust all of these and similar myths through effective communication channels and appropriate advertising. 

Male infertility and its market verticals

Male infertility can be characterized by low sperm count, low presence of motile sperm, Azoospermia. There are several lifestyle habits that increase the potential risks of male infertility; including stress, excessive alcohol intake, drug addictions, smoking, obesity, and environmental toxins. The male infertility market at present expects a fresh boost, given the rise in situational awareness among men. Regional avenues expect increases consumer base with recent rise in medical tourism cross national borders.

Segmentation of male infertility market is based upon the sundry diagnostic and therapeutic techniques. These include DNA fragmentation, computer-assisted semen analysis, oxidative stress analysis, microscopic examination, sperm penetration test, and sperm agglutination test. Report forecasts that the DNA fragmentation market would lead in terms of market share and market revenue. This can be credited to its high level of accuracy in identifying infertility among men.

Geographical segmentation is performed for a detailed study of the market over North America, Europe, Asia-Pacific, and rest of the world (RoW). Some regions have a better access to both technology and equipment, while developing regions are yet to gain access to the same. Owing to the use of advanced techniques in male infertility treatment, North American markets would lead in terms of revenue generation up till 2020. However, due to rising awareness about male infertility and its treatment, Asia-Pacific and the RoW would register highest CAGR during the analysis period. 

For more information visit at: https://www.alliedmarketresearch.com/male-infertility-market

Gauging pillars of male infertility market growth

Like any other medical segment, technical inventions lead the list of driving forces. In recent news, the Trak comes as a portable gadget that allows performing a sperm count for male ejaculates. Developed by the startup Sandstone Diagnostics, it is uses centrifugation to settle down sperm cells for measuring. Such innovations, available to the consumer segment direct from the manufacturing facilities, along with point of sale stores, helps the male population conduct the tests on their own, rather than shying away from the thought of facing a third-party with the issue. Moreover, it poses as a comparatively cheaper alternative for primary testing rather than the extensive expert consultations that have to be individually conducted for both partners. However, such devices would never possible eliminate the reasons to visit a doctor in person. In an industry where female fertility monitoring and evaluation devices dominate over alternatives for male, new entrants have a strong chance of placing themselves strongly in the market. 

While existing market players require to strengthen their position by impactful awareness programs, and advanced technology to support their portfolio expansions. The AMR report, profiles important companies that conduct business in the male infertility market. The most prominent of all are ASKA Pharmaceutical Co. Ltd, ZydusCadila Healthcare Limited, Access Pharmaceuticals, Inc., Intas Pharmaceuticals Ltd., Pantarhei Bioscience B, Cordex Pharma, Inc., Merck Serono, Halotech DNA SL, SCSA diagnostics, and Andrology Solutions. Successful placement of novice devices remain a challenge for the manufacturers throughout the forecast period. Overall benefits for the industry also source in from strong healthcare and awareness policies from the government with increased focus on elevating all social taboos. Insurance facilities have a huge role to play in the growth of the industry, if they decide upon extending medical coverage for population seeking pricey reproductive healthcare facilities. Financial grants from corporate investors would also foster development activities in this segment.

Related Post